Summary
In order to compare the beta blockers bisoprolol and diazepam in the treatment of cardiac neurosis, 40 patients (16 males and 24 females, mean age: 39 ± 11 years) were examined in a double-blind, crossover study. Following a 4-week placebo period, patients were randomized to receive either bisoprolol 10 mg daily or diazepam 5 mg twice daily for 4 weeks. After a second 4-week washout period on placebo, patients were switched to the alternative regimen for a further 4 weeks. At the end of the placebo periods and during each phase of treatment, the following parameters were evaluated: somatic symptoms by self-assessment questionnaire, anxiety state by Hamilton rating scale, reaction time to both aroustic and visual stimuli, blood pressure, and heart rate. Both treatments were effective in reducing somatic symptoms of cardiac neurosis, but bisoprolol was significantly more effective than diazepam (p < 0.01). On the contrary, diazepam was superior to bisoprolol in improving the Hamilton scale related to psychic symptoms. Only diazepam prolonged reaction times. Both treatments were well tolerated; however, 12 patients complained of drowsiness and nine of sedation under diazepam. In conclusion, bisoprolol appeared to be as effective as diazepam in the treatment of cardiac neurosis, but with better effects on somatic symptoms and without affecting patients' psychomotor performance.
Similar content being viewed by others
References
Da Costa JM. On irritable heart: A clinical study of a functional cardiac disorder and its consequences. Am J Med Sci 1871;61:2–8.
Homgren A, Johnson B, Levander L. Low physical working capacity in suspected heart cases due to inadequate adjustment on peripheral blood flow. Acta Med Scand 1957;159:413–421.
Gorlin R, Brachfeld N, Turner JD, et al. The idiopathic high cardiac output state. J Clin Invest 1959;38:2145–2157.
Gorlin R. The hyperkinetic heart syndrome. JAMA 1962;182:823–826.
Editorial. The hyperkinetic heart. Lancet 1982;2:967–968.
Hartshorne H. On heart disease in the army. Am J Med Sci 1984;48:89–95.
Masini U. La nevrosi cardiaca, una sindrome mal definita. Proposta di una classificazione nosografica. Cardiologia 1985;30:67–71.
Breggin PR. The psychophysiology of anxiety. J Nerv Ment Dis 1964;139:558–568.
Mola B. Cardiac neurosis recognition and management. Cardiovasc Clin 1971;2:222–230.
Patron G, Duperier CL, Degeorges M. Le traitment de l'asthenie neuro-circulatoire. Rev Prat 1976;26:261–268.
Frohlic ED, Dustan HP, Page IH. Hyperdynamic betaadrenergic circulation state. Arch Intern Med 1969;123:1–7.
Frohlic ED, Tarazi RC, Dustan HF. Hyperdynamic betaadrenergic circulatory state increased beta-receptor responsiveness. Arch Intern Med 1969;123:1–7.
Bollinger A. Treatment of the hyperkinetic heart syndrome with propranolol. Cardiologia 1966;49 (Suppl 2):68–82.
Schweitzer P, Pivonka M, Gregorova J. The hemodynamic effects of beta-adrenergic blockade in patients with neurocirculatory asthemia. Cardiologia 1968;52:246–251.
Bourne HR, Thomson PD, Melmon K. Diagnosis and treatment of beta-adrenergic receptor hyperresponsiveness. A critical appraisal. Arch Intern Med 1970;125:1063–1066.
Marsden CW. Propranolol in neurocirculatory asthenia and anxiety. Postgrad Med 1971;47(Suppl):100–105.
Furberg CD. Beta-adrenergic receptor blocking drugs in hypertrophic cardiomiopathy, autonomically mediated cardiovascular functional disorders and Fallot's tetralogy. Drugs 1974;7:106–117.
Wolf E, Brown K, Stern S. Effects of beta-receptor blocking agents propranolol and practolol on ST changes in neurocirculatory asthenia. Br Heart J 1974;36:872–879.
Guazzi M, Polese A, Magrini F, et al. Long-term treatment of hyperkinetic heart syndrome with propranolol. Am J Med Sci 1975;270:465–474.
Rimon R, Kampman R, Viukari M. Propranolol in the treatment of neurocirculatory asthenia: An open pilot study. Isr J Psychiatry Relat Sci 1979;17:144–148.
Tyrer P. Use of beta-blocking drugs in psychiatry and neurology. Drugs 1980;20:300–308.
Noyes R. Beta-blocking drugs and anxiety. Psychosomatics 1982;23:155–170.
Michael JA. A placebo-controlled, double-blind trial of oxprenolol versus diazepam in the treatment of anxiety and stress. In: Kielholz P, ed. Psychosomatic cardiovascular disorders. Berne: Hans Huber, 1981:191–196.
Suzman MM. Use of beta-adrenergic receptor blocking agents in psychiatry. In: Neuropharmacology of central nervous system and behavioral disorders. London: Academic Press, 1981: 339–391.
Baathen LR, Gisholt K, Hellebo R, et al. Effect of alprenolol in patients with neurocirculatory asthenia: A controlled double-blind study in general practice. Pharmatherapeutica 1977;1:381–388.
Meibach RC, Mullane SF, Binstock G. A placebo-controlled multicenter trial of propranolol and chlordiazepoxide in the treatment of anxiety. Curr Ther Res 1987;41:1965–1976.
Lader MH, Tyrer PJ. Central and peripheral effects of propranolol and sotalol in normal human subjects. Br J Pharmacol 1972;45:557–560.
Knapp E, Raas E, Aigner A, Baumgartl P. Practolol (ICI 50172) zur oralen Therapie Sympatikotonen Kreislaufdysregulationen. Z Kardiol Angiol 1973;51:117–119.
Thulesius O, Hansson R, List E. Cardiospecific betaadrenergic blockade in the treatment of nervous heart symptoms. Curr Ther Res 1973;15:805–814.
Saul P, Jones BP, Edwards KG, Tweed JA. Randomized comparison of atenolol and placebo in the treatment of anxiety: A double-blind study. Eur J Clin Pharmacol 1985;28: (Suppl):109–110.
Chang PC, Van Veen S, Vermely P, Van Brummelen PE. Beta1-selectivity of bisoprolol compared with atenolol. Br J Clin Pharmacol 1987;23:625P-626P.
Leopold G, Ungethum W, Pabst J, et al. Pharmacodynamic profile of bisoprolol, a new beta1-selective adrenoceptor antagonist. Br J Clin Pharmacol 1986;22:293–300.
Prichard BN. Bisoprolol: A new beta-adrenoceptor blocking drug. Eur Heart J 1987;8(Suppl M):121–129.
Hamilton H. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;2:356–362.
Hallstrom C, Treasaden I, Edwards JC, et al. Diazepam, propranolol and their combination in the management of chronic anxiety. Br J Psychiatry 1981:139:417–421.
Tyrer PJ, Lader MH. Responses to propranolol and diazepam in somatic and psychic anxiety. Br Med J 1974;2:14–24.
Tyrer PJ, Lader MH. Physiological and psychological effects of propranolol and diazepam in anxiety. Br J Clin Pharmacol 1974;1:379–385.
Granville-Grossman KL. Propranolol, anxiety and the centeral nervous system. Br J Clin Pharmacol 1974;1:361–363.
Hayes PE, Schulz SC. The use of beta-adrenergic blocking agents in anxiety disorders and schizophrenia. Pharmacotherapy 1983;3:101–117.
Granville-Grossman L, Turner P. The effect of propranolol on anxiety. Lancet 1966;1:788–790.
Cruickshank JM, Prichard BN. Beta-blockers and the hyperkinetic heart syndrome or neurocirculatory asthenia. In: Cruickshank JM, Prichard BN, eds. Beta-blockers in clinical practice. New York: Churchill Livingstone, 1988: 658–659.
Frishman WH, Teicher W. Beta-adrenergic blockade. An update. Cardiology 1985;72:280–296.
Prichard BN, Tomlinson B. The additional properties of beta-adrenoceptor blocking drugs. J Cardiovasc Pharmacol 1986;8(Suppl 4):S1-S15.
Cruickshank JM. Clinical importance of cardioselectivity and lipophilicity of beta-blockers. Am Heart J 1980;100: 160–175.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fogari, R., Zoppi, A., Corradi, L. et al. Comparison of bisoprolol and diazepam in the treatment of cardiac neurosis. Cardiovasc Drug Ther 6, 249–253 (1992). https://doi.org/10.1007/BF00051146
Issue Date:
DOI: https://doi.org/10.1007/BF00051146